Home > Insider Trading > Filing (0001209191-15-018745)

Filing Details

Accession Number:: 0001209191-15-018745
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-02-25 18:11:42
Reporting Period:: 2015-02-23

Filing Date:: 2015-02-25
Accepted Time:: 2015-02-25 18:11:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1281895	Inotek Pharmaceuticals Corp	ITEK	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1356034	Devon Park Bioventures Lp	1400 Liberty Ridge Drive, Suite 103 Wayne PA 19087	No	No	Yes	No
1610919	Devon Park Associates, L.p.	1400 Liberty Ridge Drive, Suite 103 Wayne PA 19087	No	No	Yes	No
1610920	Devon Park Associates, Llc	1400 Liberty Ridge Drive, Suite 103 Wayne PA 19087	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-02-23	2,323,610	$0.00	2,323,610	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-02-23	105,933	$0.00	2,429,543	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-02-23	814,166	$6.00	3,243,709	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series AA Convertible Preferred Stock	Disposition	2015-02-23	7,432,720	$0.00	2,323,610	$0.00
Common Stock	Convertible Promissory Notes	Disposition	2015-02-23	626,943	$0.00	105,933	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Consists of the following shares of Common Stock issued upon conversion of shares of Series AA Convertible Preferred Stock ("Series AA") and accrued and unpaid dividends thereon, on a 4.05783-for-1 basis, upon the closing of the Issuer's initial public offering: 2,323,610 shares held directly by Devon Park Bioventures LP. The shares of Series AA had no expiration date.
Securities are held directly by Devon Park Bioventures, LP. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, LP. Messrs. Marc Ostro, Christopher Moller and Devang Kantesaria, a member of the Issuer's board of directors, are the founding members and managing members of Devon Park Associates, LLC. Each such managing member (the "Founding Member") may be deemed to have shared voting and investment power over the shares beneficially owned by Devon Park Bioventures, LP. Each Founding Member disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Founding Members are the beneficial owners of such securities for Section 16 or any other purpose.
The outstanding principal amount and all accrued and unpaid interest under the Convertible Promissory Notes were automatically converted upon the closing of the Issuer's initial public offering into shares of Common Stock at the initial public offering price of $6.00 per share. The Convertible Promissory Notes had no expiration date. The number of shares of Common Stock as shown in column 4 of Table I consists of 105,933 shares held directly by Devon Park Bioventures LP.
Consists of the following shares purchased at the Issuer's initial public offering: 814,166 shares held directly by Devon Park Bioventures LP.